Study: THC and CBD Combined With Temozolomide May Help Treat Glioblastoma

Administration of THC and CBD in combination with the chemotherapy drug temozolomide may provide a potential treatment option for glioblastoma multiforme, according to a study published by the journal Biochemical Pharmacology.

“Glioblastoma multiforme (GBM) is the most frequent and aggressive type of brain tumor due, at least in part, to its poor response to current anticancer treatments”, states the study’s abstract. “These features could be explained, at least partially, by the presence within the tumor mass of a small population of cells termed Glioma Initiating Cells (GICs) that has been proposed to be responsible for the relapses occurring in this disease.” Thus, “the development of novel therapeutic approaches (and specifically those targeting the population of GICs) is urgently needed to improve the survival of the patients suffering this devastating disease.”

Researchers state that “Previous observations by our group and others have shown that Δ9-Tetrahydrocannabinol (THC, the main active ingredient of marijuana) and other cannabinoids including cannabidiol (CBD) exert antitumoral actions in several animal models of cancer, including gliomas. We also found that the administration of THC (or of THC + CBD at a 1:1 ratio) in combination with temozolomide, the benchmark agent for the treatment of GBM, synergistically reduces the growth of glioma xenografts.”

Read moreStudy: THC and CBD Combined With Temozolomide May Help Treat Glioblastoma

Study: Marijuana Extract Associated With Improved Survival Rates In Glioma Patients

By NORML

Brain tumor patients treated with marijuana extracts have increased survival rates compared to those who go untreated; this is according to newly released research.

Twenty-one patients with recurrent glioblastoma multiforme and who were undergoing conventional anti-cancer treatment participated in the study. Patients received either a proprietary cannabis extract containing a combination of THC and CBD or a placebo.

“[P]atients with documented recurrent GBM treated with THC:CBD had an 83 percent one year survival rate compared with 53 percent for patients in the placebo cohort,” the company summarized in a press release. “Median survival for the THC:CBD group was greater than 550 days compared with 369 days in the placebo group.”

Read moreStudy: Marijuana Extract Associated With Improved Survival Rates In Glioma Patients